Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
3
BL Mistal, Lokesh Agarwal, Soumya Chhajed
Analysts
8
Abhishek Singhal, Amit Mahendale, Disha, Neelam Punjabi, Preet, Ramesh, Rohit, Sanchita Sood
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹440 crores | +58% YoY, +16% QoQ vs ₹378 crores Q4FY26; driven by Retailer Shakti (+48% YoY) and Sasta Sundar (+44% YoY); July exit run rate ₹150+ crores/month |
| Gross Profit | ₹34 crores | +64% YoY, +24% QoQ |
| Gross Margin | 7.8% | +50 bps from 7.3% in Q4FY26; FY27 full-year target 8%+; ~12% expected at scale |
| EBITDA | -₹15 crores | Loss narrowed from -₹20 crores in Q4FY26; impacted by higher employee and other operating expenses |
| EBITDA Margin | -3.4% | Improved from -5.5% in Q4FY26 |
| PAT | ₹2 crores | Turned positive from -₹13 crores loss in Q4FY26; below ₹26 crores PAT in Q1FY26; 7–8% of revenue is treasury income |
| JITO Revenue | ₹79 lakhs | Up from ₹25 lakhs in Q4FY26 (~200% QoQ growth); ~50% gross margin |
| Working Capital Cycle | ~28 days | Equivalent to ~8% of revenue; capital-efficient scaling model |
| Active Pharmacies | ~40,000 | Of 75,000 registered in last 30 days; average wallet share ~2%; 3–4% market share in West Bengal |
Geographic & Segment Commentary
- Retailer Shakti (B2B): Grew 48% YoY and remains the principal growth engine; 69.4% of orders above ₹2,500 and 42.4% above ₹5,000, signaling retailers are consolidating procurement on the platform. Gross margin at 7.8%; EBITDA close to breakeven with positive EBITDA guided for Q3 FY27.
- Sasta Sundar (B2C): Grew 44% YoY; 69.2% of orders above ₹1,000 with capability to serve smallest orders. Operating via ~350 Health Buddy franchisees (no inventory held); management invests ~15% of revenue to build brand, with burn split ~25–30% marketing and 40–45% tech.
- Geographic Expansion: ~70% of revenue remains from West Bengal (3–4% market share, targeting ~7%); 67% of Retailer Shakti and 78% of Sasta Sundar business from tier 2/3 markets. Expanded into Odisha, Jharkhand, Bihar, Chhattisgarh, Haryana, UP, Rajasthan and Northeast — with Northeast the fastest-growing region.
Company-Specific & Strategic Commentary
- JITO Private Label Platform: Priced up to 60% below leading branded alternatives; revenue tripled QoQ to ₹79 lakhs at
50% gross margin; 19 Health Buddies converted to JITO with 25 more in pipeline (50% conversion within 3 months); new pure-play JITO franchisee channel being built. - AI-Enabled Retailer SaaS: "Retailer" AI tool launching this quarter targeting reduction of pharmacy inventory from 30 days to 5–6 days via automated ordering; intended to double pharmacy wallet share (~2% currently) and eliminate retailer credit dependence.
- Fulfillment Infrastructure: Current plus side extensions support ₹2,500–3,000 crores annual revenue; Noida warehouse starting August 17; Guwahati capacity expansion underway; construction starting in Patna and Lucknow; all riders on payroll as full-time employees; ~90% current capacity utilization.
- Capital Efficiency Model: No revenue acquired inorganically — selling 90% of revenue (Sasta Sundar to Flipkart) funded treasury, avoided dilution; focus on cash flow over EBITDA by eliminating depreciation/interest costs via digital distribution.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Retailer Shakti EBITDA | Positive EBITDA by Q3 FY27 | Currently near breakeven; driven by operating leverage and continued scaling (CFO guidance) |
| Gross Margin (FY27) | 8%+ full year | Up from 7.8% Q1; supported by JITO ramp, wallet share gains and volume procurement (CEO guidance) |
| Long-term Gross Margin | ~12% | Industry-consistent for B2B and B2C net of last-mile costs; driven by volume, wallet share, private label (CEO) |
| FY27 Revenue | Best year in company history | July run rate ₹150+ crores/month; crossed highest quarterly turnover since Flipkart era (CEO) |
| Fulfillment Capacity | ₹2,500–3,000 crores revenue | Maintained with current + side extensions; large CapEx warehouses needed beyond this for seamless large-scale operations (CEO) |
| Sasta Sundar Burn | ~₹100 crores through FY27–28 | Allocated to brand, team, expansion territories; not expected to be EBITDA-positive near term (CEO) |
Risks & Constraints
| Risk | Context |
|---|---|
| Sustained B2C Burn | Sasta Sundar investment of ~₹100 crores through FY27–28 with 40–45% toward tech; consolidated EBITDA negative at -₹15 crores. Management explicitly stated EBITDA is not a priority for 2–3 years and will not cut tech investment. |
| Geographic Concentration | ~70% of revenue from West Bengal at only 3–4% market share; new markets still early in ramp. Management cites Northeast as fastest growing (IPM-driven demand from ~80 crore new medicine users). |
| Capacity Utilization at ~90% | Current fulfillment infra near capacity limits; side extensions bridge until ₹2,500–3,000 crores revenue, but new large warehouses need to come online to sustain growth. Construction delays (2–3 months lead for Patna/Lucknow) could constrain near-term growth. |
| Low Wallet Share & Competition | Retailer Shakti wallet share only ~2% of pharmacy procurement; competitors with physical distribution and easier gross margin reporting may appear stronger on reported EBITDA, obscuring Healthex's capital efficiency framework. |
Q&A Highlights
Retailer Shakti Margins & Breakeven Path
- Question: What were Retailer Shakti's gross margin and EBITDA margin in Q1FY27? (Sanchita Sood)
- Answer: Gross margin ~7.8%; EBITDA close to breakeven, positive EBITDA expected in Q3 FY27 (Lokesh Agarwal).
Revenue Projections
- Question: Any revenue aspiration for FY27 and FY28? (Sanchita Sood)
- Answer: No yearly projections disclosed; July ended with ₹150+ crores revenue, from which run-rate projections can be extrapolated (BL Mistal).
Gross Margin Trajectory & Cost Structure
- Question: How does gross margin ramp toward double digits and what operating leverage exists? (Abhishek Singhal)
- Answer: Industry gross margin ~12%; JITO at ~50% GM plus volume, wallet share and private label expansion will drive expansion. Focus is cash flow, not EBITDA — digital distribution eliminates depreciation and interest costs, moving directly from gross margin to administrative costs (BL Mistal).
JITO Scale-Up Potential
- Question: Could JITO reach 5–6% of sales in three years, adding ~100 bps to gross margins? (Abhishek Singhal)
- Answer: Internal projections suggest surpassing these figures, but no specific guidance — company is evolving with multi-new initiatives ahead (BL Mistal).
Regional Mix & New Market Ramp
- Question: How is revenue split by region and how are new markets ramping? (Abhishek Singhal)
- Answer: ~70% from West Bengal, 30% from new markets; Northeast fastest growing. Expansion into Odisha, Jharkhand, Bihar, Chhattisgarh (from West Bengal) and Haryana/UP/Rajasthan (from Noida); new warehouses planned for Patna, Ranchi and Chhattisgarh. IPM data shows Jharkhand as highest-growth region — reflecting ~80 crore first-time medicine users (BL Mistal).
EBITDA Breakeven Timeline Clarification
- Question: Previously guided 1–2 years to EBITDA breakeven; now extending to 2–3 years — why? (Ramesh)
- Answer: Breakeven guidance was specifically for Retailer Shakti, on track for this year. Consolidated breakeven including B2C was never committed — burn is concentrated in Sasta Sundar (BL Mistal).
Warehouse Capacity & Last-Mile Logistics
- Question: What top line can current infrastructure sustain and how is automation replicated? (Abhishek Singhal)
- Answer: Current infrastructure plus side extensions support ₹2,500–3,000 crores annual revenue. Noida warehouse starts August 17; Guwahati capacity expanding; Patna/Lucknow construction in 2–3 months. Pharmacy warehouses are licensed, hygienic and delicate (50,000 SKUs) — owned facilities preferred to avoid lease/transition losses; riders are on company payroll (BL Mistal).
Capacity Utilization & NCLT Approvals
- Question: Current capacity utilization and any licensing/permitting issues? (Preet)
- Answer: ~90% capacity utilization; no licensing or authority issues; NCLT merger/demerger scheme approval on track — applications and questions underway (BL Mistal).
Market Share & Wallet Share
- Question: What is current market share in Bengal and target? What is pharmacy wallet share? (Neelam Punjabi)
- Answer: 3–4% market share in Kolkata/West Bengal, targeting ~7% in 2–3 years. ~40,000 pharmacies active in last 30 days (of 75,000 registered); average wallet share ~2%, targeted to double via AI-enabled Retailer SaaS (BL Mistal, Lokesh Agarwal).
Key Takeaway
Q1 FY27 was the best quarter in Healthex's history: revenue up 58% YoY to ₹440 crores, gross margin expanding 50 bps to 7.8%, and PAT turning positive at ₹2 crores (vs -₹13 crores in Q4FY26, aided by ~7–8% treasury income). Retailer Shakti grew 48% YoY and is guided to positive EBITDA by Q3FY27, while Sasta Sundar grew 44% YoY with deliberate brand/tech investment. JITO private label revenue tripled QoQ to ₹79 lakhs at ~50% margins, anchoring the path toward ~12% long-term gross margins. With ~70% of revenue still from West Bengal, expansion across 8+ states (Northeast fastest growing) underpins management's FY27 guidance as the best year in company history, supported by a ₹150+ crores monthly run rate in July. Watch items include ~₹100 crores planned B2C burn through FY27–28, ~90% warehouse capacity utilization, and the upcoming AI-enabled Retailer SaaS launch targeting doubled wallet share from ~2%.